Navigation Links
Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
Date:9/25/2007

LONDON, Sept. 25 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class, novel non-steroidal anti-inflammatory drugs, today announced it has appointed Dr. Johnson Lau and Dr. David Sidransky to its board of directors.

Dr. Johnson Lau (MBBS, MD, FRCP) brings a wealth of experience from the medical, pharmaceutical and corporate fields, having a distinguished background in both academic medicine and executive-level management of pharmaceutical and biotechnology companies. Dr. Lau previously served Schering-Plough, ICN Pharmaceuticals and its subsidiary Ribapharm, and is currently a senior advisor to Novartis. He was formerly a managing director of healthcare investment banking of Roth Capital Partners. Dr. Lau also serves as a member of the board of directors of Chelsea Therapeutics, VioQuest Pharmaceuticals, XenoBiotic Laboratories and Kinex Pharmaceuticals. Dr. Lau is a Fellow of the Royal College of Physicians of the United Kingdom. He received both his medical degree and doctoral degree from the University of Hong Kong.

Dr. David Sidransky (MD) is the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is also a professor of oncology, otolaryngology-head and neck surgery, cellular and molecular medicine, urology, and genetics and pathology at the university. He is currently vice-chairman of the board of directors of ImClone Systems, lead independent chairman at Alfacell Inc. and serves on the board of directors of Zila Inc. and Xenomics. Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of both private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the National Institute of Dental and Craniofacial Research and is a member of the Recombinant DNA advisory committee at the National Institutes of Health. Dr. Sidransky sits on numerous editorial boards and has served as senior editor of several cancer-related journals. He is certified in internal medicine and medical oncology by the American Board of Medicine.

"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board," said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi- functional anti-inflammatory drugs (MFAIDs). The company's objective is to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, pulmonary and gastro- intestinal inflammatory diseases. For more information please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - persons in the business of disseminating information.

SOURCE: Morria Biopharmaceuticals Plc

UK CONTACT: Yuval Cohen, President

53 Davies Street, London, W1K 5JH, United Kingdom

Tel: +44 (0) 207 152 6341 or info@morria.com

US CONTACT: Greg Tiberend

Richard Lewis Communications, Inc.

35 West 35 St., Suite 505, New York, NY 10001

Tel: +1 212-827-0020 or gtiberend@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):